Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.56 |
| ▸ | MAG | P20916 | 11/20 | 0.56 |
| ▸ | SELL | P14151 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.51 |
| ▸ | SELE | P16581 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19427378 | 0.95 | SIGLEC7 (0.63) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL24495284 | 0.91 | SIGLEC7 (0.59) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL12138042 | 0.90 | SIGLEC7 (0.58) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL18430742 | 0.88 | SIGLEC7 (0.64) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL16491226 | 0.88 | SIGLEC7 (0.61) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL13884986 | 0.86 | SIGLEC7 (0.59) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL12313945 | 0.86 | SIGLEC7 (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL18806942 | 0.85 | SELP (0.57) | SIGLEC7MAGSELP | |
| SCHEMBL30654069 | 0.85 | SELP (0.57) | SIGLEC7MAGSELP | |
| SCHEMBL30653688 | 0.85 | SELP (0.57) | SIGLEC7MAGSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263576-B2 | A carbohydrate linked to a fluorophore through a 2-amido-2-(1-hydroxyalkyl)ethoxy linkage; inhibition of caveolar endocytosis, plasma membrane microdomain formation, virus binding and infection, transmembrane signaling, and integrin function in cells; anticarcinogenic and antiinflammatory agents | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2012-09-11 | — | — | US | disclosed |
| US-20080064645-A1 | Non-Natural Sphingolipid Analogs and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064645-A1 | Non-Natural Sphingolipid Analogs and Uses Thereof | SGMS1, BST2, SELPLG | SIGLEC7 4/4885MAG 121/4885SELL 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.